Legend Biotech stock: FDA clears LB2501. What it means for Legend Biotech stock

Published on 10/23/2026 at 04:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

FDA cleared LB2501 on October 15, 2026 for a Phase 1/2 study. Legend Biotech stock posted revenue of USD 387.50 million, up 51.90 percent year over year.

Pipeline and operating scale

FDA clearance on October 15, 2026 supports a Phase 1/2 study for LB2501.
Second-quarter 2026 revenue reached USD 387.50 million, up 51.90 percent year over year.
Legend Biotech had a USD 3.5 billion market capitalization and a USD 16.24 to USD 37.50 52-week range as of October 22, 2026.

LEGN, US52490G1022, Illustration mit AI erstellt.

Legend Biotech (ISIN US52490G1022) said on October 15, 2026 that the U.S. Food and Drug Administration had cleared its investigational new drug application for LB2501, an in vivo CAR-T therapy. The announcement supports a planned U.S. Phase 1/2 study, according to GlobeNewswire.

Three milestones shape the pipeline

On August 11, 2026, Legend Biotech reported second-quarter revenue of USD 387.50 million, an increase of 51.90 percent from the same period a year earlier, according to MarketBeat. On October 1, 2026, the company launched one ELITE grant program, while the October 15 FDA clearance added a Phase 1/2 development path for LB2501.

The sequence matters because Legend Biotech is pairing commercial CAR-T execution with a platform aimed at producing CAR-T cells inside the patient after a single infusion. The company develops and markets CARVYKTI with Johnson & Johnson, while LB2501 expands its pipeline beyond the lead multiple-myeloma treatment.

What does LB2501 change?

The planned Phase 1/2 study will examine safety, tolerability, pharmacokinetics and preliminary efficacy. LB2501 is designed to target both CD19 and CD20, a two-target approach that the company links to potential defenses against treatment resistance.

When are results due?

Legend Biotech is scheduled to report its next results on November 11, 2026, according to a dated earnings-calendar listing from Yahoo Finance. That date gives investors the next formal checkpoint for revenue growth, earnings and development spending.

Market value frames the opportunity

Legend Biotech had a USD 3.5 billion market capitalization as of October 22, 2026. Its 52-week range was USD 16.24 to USD 37.50 on the same date, leaving the FDA milestone to be weighed against a share price that remained well below the yearly high.

The further course of trading is shown by the continuously updated real-time quote of Legend Biotech stock.